Zoetis (ZTS) Saham Harga
Zoetis Harga
Pendapatan tumbuh 8,0% per tahun selama 16 tahun terakhir menjadi 9,47 miliar USD. Laba per saham tumbuh 24,5% per tahun selama 15 tahun terakhir. margin bersih Zoetis saat ini 28,2%, naik dari 26,2% beberapa tahun lalu. Zoetis saat ini menawarkan imbal hasil dividen sekitar 2,52%. Rasio pembayaran sekitar 33% dari laba. Dividen tumbuh 21,4% per tahun selama 12 tahun terakhir. Target harga median analis adalah 85,00 USD, di atas harga saat ini sebesar 7,1%. Dari 22 analis, 9 merekomendasikan beli — konsensus keseluruhan Tahan.
Harga saham Zoetis
Akses data ini lewat Eulerpool API
100.000 permintaan/bulan gratis · tanpa kartu
Model bisnis dan analisis saham Zoetis
Pertanyaan yang sering diajukan tentang saham Zoetis
Zoetis Inc. operates as a leading animal health company globally. The business model of Zoetis Inc. revolves around discovering, developing, manufacturing, and marketing a diverse range of animal health products and vaccines. With a focus on improving the health and well-being of animals, Zoetis aims to provide innovative solutions that enhance the health, productivity, and performance of livestock and companion animals. By offering a wide portfolio of products and services, Zoetis caters to the needs of veterinarians, livestock producers, and pet owners, thereby contributing to the overall welfare and sustainability of the animal health industry.
Zoetis Inc primarily operates in the animal health industry.
The main competitors of Zoetis Inc in the market are Merck & Co Inc, Elanco Animal Health Inc, and Boehringer Ingelheim GmbH.
Zoetis Inc is a leading global animal health company that specializes in the discovery, development, manufacture, and commercialization of a wide range of veterinary medicines and vaccines. Founded in 1952, Zoetis has a rich history of providing innovative solutions to improve the health and well-being of animals. With a strong commitment to research and development, the company has introduced numerous cutting-edge products and technologies that have revolutionized the field of animal health. Zoetis operates in more than 100 countries, serving veterinarians, livestock producers, and pet owners worldwide. This dedication to delivering high-quality, safe, and effective animal healthcare solutions has established Zoetis as a trusted name in the industry.
Zoetis Inc., a leading animal health company, has achieved several significant milestones in its history. Since its establishment in 2013 as a spin-off from Pfizer, Zoetis has continuously strived for innovation and growth. Some noteworthy milestones include its successful initial public offering (IPO) in 2013, becoming the largest animal health IPO in history. The company has also established itself as a global leader in animal health, expanding its presence in various markets worldwide. Additionally, Zoetis has consistently focused on research and development, introducing innovative products and solutions to address the health and well-being of animals. Through its dedication and expertise, Zoetis Inc. continues to make remarkable progress in the animal health industry.
Zoetis Inc., a leading animal health company, operates in various countries and regions worldwide. With a strong global presence, Zoetis primarily serves customers in North America, Europe, Africa, Asia, and Latin America. The company's extensive network allows it to deliver innovative animal health solutions and support to a diverse range of customers across these regions. Zoetis' commitment to expanding its reach and impact in the animal health industry is reflected in its presence and operations throughout these key locations.
Zoetis Inc represents a strong set of values and corporate philosophy. As a global animal health company, Zoetis Inc is committed to improving the health and well-being of animals by providing innovative products and services. With a focus on sustainability, they strive to make a positive impact on the world we live in. Zoetis Inc values integrity, accountability, collaboration, and customer focus. Their dedication to research and development ensures the delivery of high-quality solutions for animal health. By constantly evolving and embracing technological advancements, Zoetis Inc remains at the forefront of the industry, dedicated to improving the lives of animals, the people who care for them, and the communities they serve.
Analis saat ini menetapkan target harga rata-rata 99,17 USD untuk saham Zoetis (median: 85,00 USD), yaitu +24,9 % terhadap harga terbaru. Konsensus didasarkan pada 22 peringkat analis.
22 analis saat ini menilai saham Zoetis: 9 merekomendasikan beli, 13 tahan, dan 0 jual. Untuk 2026, analis memperkirakan Zoetis menghasilkan pendapatan 9,27 miliar USD dan laba per saham 6,29 USD.
Dengan kurs saat ini, saham Zoetis diperdagangkan pada 71,15 EUR (79,40 USD).
Saham Zoetis (ZTS) tercatat di 10 bursa, termasuk: NYSE (ZTS), London (0M3Q.L), SIX (Zürich) (ZOE.SW), XETRA (ZOE.DE), Frankfurt (ZOE.F), München (ZOE.MU), Düsseldorf (ZOE.DU), Wien (ZOTS.VI).
Zoetis Inc is a leading company in the animal health industry that focuses on the development, manufacturing, and marketing of pharmaceuticals, vaccines, and diagnostic tests for animals. The company was founded in 1952 and is based in Parsippany, New Jersey. Zoetis operates in various segments including cattle production, swine production, poultry research and diagnostics, small animal practice, equine and livestock practice, and ectoparasiticides. The company offers several products that appeal to veterinarians and farmers. In the cattle range, Zoetis offers products such as EXCEDE, an injection that ensures sustained efficacy against pathogens in cattle, DRAXXIN, an injectable antibiotic for treating cattle with respiratory diseases and BRD, and LUTALYSE, a hormone that helps cattle breeders and livestock dealers during calving. In the swine production area, Zoetis offers products such as RESFLOR GOLD, a combination of antibiotics used for treating respiratory diseases, FOSTERA, a vaccine that provides immunity against Porcine Reproductive and Respiratory Syndrome (PRRS) and facilitates the approval of PRRS-infected swine, and DRAXXIN, a treatment for swine with respiratory disease. Zoetis is also involved in poultry research and diagnostics. Products such as FLOKILL, a medication for treating coccidiosis in chickens, Amprol, a medication for treating coccidiosis in chickens, Zeppelin, a test kit for identifying salmonella in poultry, and Bio-Chr, a feed additive that increases egg production in laying hens. In the small animal practice, Zoetis offers products such as Simparica, a medication for parasites like ticks and fleas in dogs, and Revolution and Proheart, both medications for parasites in dogs and cats. Zoetis also offers products for horses and livestock, including EQUIOXX, an anti-inflammatory for horses with arthritis and kissing spine, and CONVENIA, an antibiotic for horses, cows, and sheep. Zoetis is not only involved in the development and marketing of animal pharmaceuticals, but also in educating animal owners and farmers. They provide resources and training for animal health and care, and provide research data and information to animal owners. Zoetis' business model is to provide animal owners and farmers with innovative products and services that improve animal health and help keep animals healthy. The company specializes in developing and offering safe and effective products for animals used in food production to secure the food supply. Overall, Zoetis has a strong position in the animal pharmaceutical and diagnostic sector. The company aims to make a positive contribution to animals and animal owners through innovative products and close collaboration with animal owners.
Pendapatan diperkirakan dari Zoetis adalah 9,27 miliar USD. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.
Laba diperkirakan dari Zoetis adalah 2,76 miliar USD. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.
Rasio harga-terhadap-pendapatan (PER) Zoetis saat ini adalah 12,63. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Zoetis.
Rasio harga-terhadap-penjualan (PSR) Zoetis saat ini adalah 3,76. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Zoetis.
Skor Kualitas AlleAktien untuk Zoetis adalah 9/10.
ISIN dari Zoetis adalah US98978V1035. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.
WKN dari Zoetis adalah A1KBYX. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.
Ticker dari Zoetis adalah ZTS. Simbol ticker digunakan untuk memperdagangkan saham Zoetis di bursa saham.
Saham Zoetis
Kelompok Peer Zoetis
Zoetis Ticker
Zoetis FIGI
Semua metrik fundamental dan analisis mendalam Zoetis
Analisis saham kami untuk saham Zoetis mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Zoetis. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.